Abstract: Association comprising agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in association with a noradrenaline reuptake inhibitor agent. Medicinal products containing the same which are useful in treating conditions associated with mood disorders.

Abstract: This invention relates to the use of nicotine receptor agonists for treating inflammatory diseases, including a variety of pulmonary diseases. Such agonists have fewer side effects than other anti-inflammatory drugs, such as steroids. Moreover, these agonists can be used alone or in combination with other anti-inflammatory drugs to alleviate pulmonary diseases.

Abstract: Cosmetic and dermatological wipes, where the wipes consist of a water-jet-consolidated and/or water-jet-impressed nonwoven material, which have been moistened with cosmetic and dermatological impregnation solutions which have a viscosity of less than 2000 mPa·s.

Abstract: A composition is disclosed which is suitable for the prevention and treatment of kidney dysfunctions and diseases and which can therefore take the form of a food supplement or of an actual medicinal drug comprising a combination of acetyl L-carnitine and propionyl L-carnitine or their pharmacologically acceptable salts.

Abstract: The present invention provides medicines for preventing or treating infectious diseases, sepsis and/or septic shock, which exhibit excellent immunostimulating effects. More specifically, the invention provides medicines for immunostimulation and infection-protection and -treatment, and/or for preventing or treating sepsis and septic shock, which comprise reduced riboflavin and/or reduced riboflavin derivative or pharmacologically acceptable salt thereof. Also provided are methods for using them in the prevention and/or treatment of infectious disorders such as sepsis and septic shock.

Abstract: The present invention concerns a method and a pharmaceutical composition for treating the symptoms associated to Parkinson's disease. The method and the pharmaceutical composition use a combination of a therapeutically effective amount of at least one of DHEA or DHEA-S in combination with a therapeutically effective amount of a dopamine precursor, such as levodopa. The present invention also concerns to the use of at least one of DHEA or DHEA-S in combination with a therapeutically effective amount of a dopamine precursor to manufacture a medicament for treating a neurodegenerative diseases.

Abstract: The present invention relates to a method of treating a central nervous system disorder, such as a mood disorder (e.g., major depressive disorder) or an anxiety disorder (e.g., general anxiety disorder, social anxiety disorder, post traumatic stress disorder, and panic disorder) with a low dose combination of escitalopram and bupropion.

Abstract: Compounds of formula (I) and salts are provided: along with pharmaceutical compositions, uses in medicine, e.g., treating disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment.

Abstract: The subject of the present invention is to provide a combination of two centrally acting analgesics, flupirtine and tramadol, or their respective pharmaceutically acceptable salts for the treament of pain.